Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer

Overview

Journal J Clin Oncol

Specialty Oncology

Date 2023 Mar 23

PMID 36952634

Authors

Kim N Chi

Dana Rathkopf

Matthew R Smith

Eleni Efstathiou

Gerhardt Attard

David Olmos

Ji Youl Lee

Eric J Small

Andrea J Pereira de Santana Gomes

Guilhem Roubaud

Marniza Saad

Bogdan Zurawski

Valerii Sakalo

Gary E Mason

Peter Francis

George Wang

Daphne Wu

Brooke Diorio

Angela Lopez-Gitlitz

Shahneen Sandhu

Affiliations

Soon will be listed here.

Abstract

Purpose: Metastatic castration-resistant prostate cancer (mCRPC) remains a lethal disease with current standard-of-care therapies. Homologous recombination repair (HRR) gene alterations, including alterations, can sensitize cancer cells to poly (ADP-ribose) polymerase inhibition, which may improve outcomes in treatment-naïve mCRPC when combined with androgen receptor signaling inhibition.

Methods: MAGNITUDE (ClinicalTrials.gov identifier: NCT03748641) is a phase III, randomized, double-blinded study that evaluates niraparib and abiraterone acetate plus prednisone (niraparib + AAP) in patients with (HRR+, n = 423) or without (HRR-, n = 247) HRR-associated gene alterations, as prospectively determined by tissue/plasma-based assays. Patients were assigned 1:1 to receive niraparib + AAP or placebo + AAP. The primary end point, radiographic progression-free survival (rPFS) assessed by central review, was evaluated first in the subgroup and then in the full HRR+ cohort, with secondary end points analyzed for the full HRR+ cohort if rPFS was statistically significant. A futility analysis was preplanned in the HRR- cohort.

Results: Median rPFS in the subgroup was significantly longer in the niraparib + AAP group compared with the placebo + AAP group (16.6 10.9 months; hazard ratio [HR], 0.53; 95% CI, 0.36 to 0.79; = .001). In the overall HRR+ cohort, rPFS was significantly longer in the niraparib + AAP group compared with the placebo + AAP group (16.5 13.7 months; HR, 0.73; 95% CI, 0.56 to 0.96; = .022). These findings were supported by improvement in the secondary end points of time to symptomatic progression and time to initiation of cytotoxic chemotherapy. In the HRR- cohort, futility was declared per the prespecified criteria. Treatment with niraparib + AAP was tolerable, with anemia and hypertension as the most reported grade ≥ 3 adverse events.

Conclusion: Combination treatment with niraparib + AAP significantly lengthened rPFS in patients with HRR+ mCRPC compared with standard-of-care AAP.

Citing Articles

Treatment of metastatic castration-resistant prostate cancer: review of current evidence and synthesis of expert opinions on radioligand therapy.

Poon D, Cheung W, Chiu P, Chung D, Kung J, Lam D Front Oncol. 2025; 15:1530580.

PMID: 40071082 PMC: 11893367. DOI: 10.3389/fonc.2025.1530580.

The Landscape of PARP Inhibitors in Solid Cancers.

Muzzana M, Broggini M, Damia G Onco Targets Ther. 2025; 18:297-317.

PMID: 40051775 PMC: 11884256. DOI: 10.2147/OTT.S499226.

Population Pharmacokinetics of Niraparib/Abiraterone Acetate Administered as Single-Agent Combination and Dual-Acting Tablets Plus Prednisone for Metastatic Castration-Resistant Prostate Cancer.

Russu A, Hazra A, Tian H, Haddish-Berhane N, Perez Ruixo J, Boulton M Adv Ther. 2025; .

PMID: 40016438 DOI: 10.1007/s12325-025-03104-y.

Impact of stereotactic body radiotherapy after progression in castrate resistant prostate cancer patients undergoing first line abiraterone treatment. A subgroup analysis from ARTO trial (NCT03449719).

Francolini G, Bertini N, Di Cataldo V, Garlatti P, Aquilano M, Caini S Prostate Cancer Prostatic Dis. 2025; .

PMID: 39972049 DOI: 10.1038/s41391-025-00950-3.

PARP inhibitor-based treatment in metastatic, castration-resistant prostate cancer (mCRPC): A systematic review and meta-analysis.

Roberto M, Di Civita M, Marinelli D, Torchia A, Cara N, Maltese G BJUI Compass. 2025; 6(1):e455.

PMID: 39877569 PMC: 11771493. DOI: 10.1002/bco2.455.

References

Scher H, Morris M, Stadler W, Higano C, Basch E, Fizazi K . Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. J Clin Oncol. 2016; 34(12):1402-18. PMC: 4872347. DOI: 10.1200/JCO.2015.64.2702. View

Washington C, Moore K . PARP inhibitors in the treatment of ovarian cancer: a review. Curr Opin Obstet Gynecol. 2020; 33(1):1-6. DOI: 10.1097/GCO.0000000000000675. View

Castro E, Romero-Laorden N, Del Pozo A, Lozano R, Medina A, Puente J . PROREPAIR-B: A Prospective Cohort Study of the Impact of Germline DNA Repair Mutations on the Outcomes of Patients With Metastatic Castration-Resistant Prostate Cancer. J Clin Oncol. 2019; 37(6):490-503. DOI: 10.1200/JCO.18.00358. View

Khalaf D, Annala M, Taavitsainen S, Finch D, Oja C, Vergidis J . Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial. Lancet Oncol. 2019; 20(12):1730-1739. DOI: 10.1016/S1470-2045(19)30688-6. View

Cui M, Gao X, Gu X, Guo W, Li X, Ma M . BRCA2 mutations should be screened early and routinely as markers of poor prognosis: evidence from 8,988 patients with prostate cancer. Oncotarget. 2017; 8(25):40222-40232. PMC: 5522317. DOI: 10.18632/oncotarget.16712. View

Polkinghorn W, Parker J, Lee M, Kass E, Spratt D, Iaquinta P . Androgen receptor signaling regulates DNA repair in prostate cancers. Cancer Discov. 2013; 3(11):1245-53. PMC: 3888815. DOI: 10.1158/2159-8290.CD-13-0172. View

Smith M, Saad F, Chowdhury S, Oudard S, Hadaschik B, Graff J . Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer. N Engl J Med. 2018; 378(15):1408-1418. DOI: 10.1056/NEJMoa1715546. View

Beer T, Armstrong A, Rathkopf D, Loriot Y, Sternberg C, Higano C . Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study. Eur Urol. 2016; 71(2):151-154. PMC: 5570461. DOI: 10.1016/j.eururo.2016.07.032. View

Clarke N, Armstrong A, Thiery-Vuillemin A, Oya M, Shore N, Loredo E . Abiraterone and Olaparib for Metastatic Castration-Resistant Prostate Cancer. NEJM Evid. 2024; 1(9):EVIDoa2200043. DOI: 10.1056/EVIDoa2200043. View

10.

Abida W, Patnaik A, Campbell D, Shapiro J, Bryce A, McDermott R . Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a or Gene Alteration. J Clin Oncol. 2020; 38(32):3763-3772. PMC: 7655021. DOI: 10.1200/JCO.20.01035. View

11.

Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev B . Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer. N Engl J Med. 2017; 377(4):352-360. DOI: 10.1056/NEJMoa1704174. View

12.

Robinson D, Van Allen E, Wu Y, Schultz N, Lonigro R, Mosquera J . Integrative clinical genomics of advanced prostate cancer. Cell. 2015; 161(5):1215-1228. PMC: 4484602. DOI: 10.1016/j.cell.2015.05.001. View

13.

Ryan C, Smith M, de Bono J, Molina A, Logothetis C, de Souza P . Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2012; 368(2):138-48. PMC: 3683570. DOI: 10.1056/NEJMoa1209096. View

14.

Castro E, Goh C, Olmos D, Saunders E, Leongamornlert D, Tymrakiewicz M . Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer. J Clin Oncol. 2013; 31(14):1748-57. PMC: 3641696. DOI: 10.1200/JCO.2012.43.1882. View

15.

Eisenhauer E, Therasse P, Bogaerts J, Schwartz L, Sargent D, Ford R . New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2008; 45(2):228-47. DOI: 10.1016/j.ejca.2008.10.026. View

16.

Asim M, Tarish F, Zecchini H, Sanjiv K, Gelali E, Massie C . Synthetic lethality between androgen receptor signalling and the PARP pathway in prostate cancer. Nat Commun. 2017; 8(1):374. PMC: 5575038. DOI: 10.1038/s41467-017-00393-y. View

17.

Hussain M, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S . Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer. N Engl J Med. 2020; 383(24):2345-2357. DOI: 10.1056/NEJMoa2022485. View

18.

Saad F, Chi K, Shore N, Graff J, Posadas E, Lattouf J . Niraparib with androgen receptor-axis-targeted therapy in patients with metastatic castration-resistant prostate cancer: safety and pharmacokinetic results from a phase 1b study (BEDIVERE). Cancer Chemother Pharmacol. 2021; 88(1):25-37. PMC: 8149334. DOI: 10.1007/s00280-021-04249-7. View

19.

Annala M, Struss W, Warner E, Beja K, Vandekerkhove G, Wong A . Treatment Outcomes and Tumor Loss of Heterozygosity in Germline DNA Repair-deficient Prostate Cancer. Eur Urol. 2017; 72(1):34-42. DOI: 10.1016/j.eururo.2017.02.023. View

20.

Ryan C, Smith M, Fizazi K, Saad F, Mulders P, Sternberg C . Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3.... Lancet Oncol. 2015; 16(2):152-60. DOI: 10.1016/S1470-2045(14)71205-7. View